The case highlights the importance of considering LADA in patients with poor glycemic control despite standard T2DM therapy, especially when autoimmune diseases are present: positive anti-GAD antibodies, low C-peptide, and improved outcomes with insulin support the diagnosis. This evidence concerns the gene INS and type 2 diabetes mellitus.